Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacology > Heart Failure > Flashcards

Heart Failure Flashcards

(89 cards)

Start Studying
1
Q

T/F patients with heart failure all have volume overload

A

FALSE

why the term “heart failure” is actually preferred over CHF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

volume coming into ventricles (end diastolic pressure)

A

preload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

resistance - left ventricle must overcome to circulate load

A

afterload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

percent of left ventricular blood ejected during each systolic contraction

A

ejection fraction (EF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a normal EF?

A

60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How is EF calculated?

A

stroke volume/end-diastolic volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HFrEF

A

systolic dysfunction

heart failure with reduced ejection fraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Disease that might lead to HFrEF

A

cardiomyopathies, CAD, valve diseases, arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HFpEF

A

diastolic dysfunction

heart failure with preserved ejection fraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Problem with HFpEF is _______ and problem with HFrEF is _________

A

1) filling (diastolic dysfn)

2) ejection (systolic dysfn)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Disease that might lead to HFpEF

A

chronic hypertension, aortic stenosis, cardiomyopathies (hypertrophic or restrictive)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the Frank-Starling mechanism?

A

the ability of the heart to change its force of contraction and therefore stroke volume in response to changes in venous return

(i.e. incr. venous return to the heart –> incr. SV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Symptoms of HF

A

FACES

Fatigue
Activity decrease
Cough (esp. supine)
Edema
Shortness of breath
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the DIET approach to pt. w/ HF?

A

Diagnose
Initiate (drugs)
Educate (diet, lifestyle)
Titrate (adjust drugs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is EF in HFrEF?

A

= 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is EF in HFpEF?

A

> /= 50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which type of HF has actually been studied in clinical trials?

A

Only HFrEF (systolic HF)

To date, efficacious therapies have not been identified for HFpEF (diastolic HF)

**HFpEF is a dx of exclusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Stage A HF (ACC-AHA Classification)

A

High risk for HF, no SHD

HTN, CAD, DM, obesity, metabolic syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Stage B HF (ACC-AHA Classification)

A

Asymptomatic HF, +SHD

previous MI, LVH, or low EF, asx valvular dz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Stage C HF (ACC-AHA Classification)

A

Symptomatic HF, +SHD

SOB, fatigue, reduced exercise tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Stage D HF (ACC-AHA Classification)

A

Refractory end-stage HF, +SHD

sx at rest despite maximal medical therapy; recurrent hospitalizations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

When would you use diuretics in HF?

A

symptomatic benefit in pt. w/ current or prior sx of HF and reduced LVEF who have evidence of fluid retention

should use used along with salt restriction

(in general should not be only therapy in stage C)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is a ceiling dose?

A

eventually, if you keep pushing the dose, you don’t get a greater benefit (this is when you would add another drug)

**Pt. with HF need higher doses of diuretics to get same response, and have diminished responses to ceiling doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

T/F, you cannot use thiazide and loop diuretics in combination

A

FALSE

esp. in pt. with HF that have diuretics resistance to loops, you may need to a thiazide in combo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What monitoring should be done in pt. on diuretics?
electrolytes (esp. potassium) loop diuretics are more powerful than thiazides and must be used with caution to avoid dehydration
26
What is the key point to remember when tx pt. with diuretics?
SODIUM RESTRICTION! if they aren't restricting sodium, the diuretics may not work b/c water will follow sodium
27
Nitroglycerine class
Nitrate - vasodilator
28
Nitroglycerine MOA (HF)
decreases preload stimulates NO
29
Nitroglycerine indications (HF)
warm and wet acute decompensated HF (ADHF), ACS
30
Nitroglycerine adverse effects
hypotension, reflex tachycardia, HA, tachyphylaxis
31
Nitroprusside class
direct vasodilator
32
Nitroprusside MOA
decreases preload and afterload stimulates NO
33
Nitroprusside indications
warm and wet acute decompensated HF (ADHF), alternative to inotropes in cold and wet ADHF
34
Nitroprusside adverse effects
hypotension or cyanide or thiocyanate toxicity
35
Nesiritide class
vasodilator, cardiac glycoside
36
Nesiritide MOA
decreases preload and afterload
37
Nesiritide indications
warm and wet acute decompensated HF (ADHF), alternative to inotropes
38
Nesiritide adverse effects
primarily hypotension (up to 1 hr), tachycardia
39
When would you Rx inotropes?
as a LAST resort w/ HF they have a lot of serious s/e and should NEVER be used in an out-patient setting
40
What are the inotrope drugs talked about in class?
dobutamine (B1 agonist) and milrinone (PDE inhibitor --> incr CO)
41
ARNI
angiotensin receptor/neprilysin inhibitor newest drug to hit the market and is going to replace ACEI significantly decreases mortality rates
42
Which therapy combo has the highest reduction in mortality rates in HF pt?
BB + ACEI/ARB + ICD (implantable cardioverter-defibrillator)+ HF educations + anticoagulation for AF
43
When are ACEI indicated with HF?
Should be used in all pt. with a reduced EF to prevent HF Recommended for all pt. with HFrEH
44
ACEI s/e
hypotensions, *cough*, renal effets, angioedema, teratogenic, hyperkalemia, rash and taste disturbance, transient incr. in serum creatinine
45
What do you need to monitor with on ACEI/ARB?
BP | BMP (electrolytes) w/in 1-2 wks
46
When is SCr concerning with ACEI/ARB tx?
a rise of >/= 0.5 needs evaluation although expect a transient 20-30% incr in SCr after starting drugs serum creatinine measures kidney fn
47
What do you need to remember when starting ACEI?
start SLOW titrate every 2-4 wks toward target dose
48
T/F you cannot use ACEI and ARB together?
TRUE it can be harmful to use them in combo
49
When would you use ARB is therapy?
- pt. with HFrEF who are ACEI intolerant - reasonable as alternatives to ACEI as first line therapy in HFrEF - pt. w/ a hx of MI and reduced EF, should be put on ACEI/ARB to prevent HR
50
How should you initiate ARB tx?
slowly
51
What is the recommendation for using ARB and ARNI in combo?
ARNI should NOT be administered concomitantly with ACE inhibitors or within 36 hr of the last dose of an ACEI
52
When are aldosterone antagonists recommended clinically?
- pt. with class II-IV HF who have LVEF = 35% | - pt. following an acute MI who have LVEF = 40% with sx of HF or DM
53
Which aldosterone antagonists are commonly used for HF?
Spironolactone/Eplerenone are "easy" drugs to prescribe for HF!!! single dose once daily, no titration necessary
54
What are the cautions with aldosterone antagonists?
1) *significant* risk of hyperkalemia ( > 5%), needs close monitoring!!! 2) 10% risk of gynaecomastia w/ spironolactone (< 1% with eplerenone)
55
C/I to eplerenone
1) serum potassium > 5.5 mEq/L at initiation 2) creatinine clearance = 30 mL/min (can start at lower dose if CrCl 31-49 mL/min) 3) concomitant use of CYP3A4 inhibitors
56
C/I to spironolactone
1) serum potassium > 5 mEq/L at initiation 2) serum creatinine >2.5 mg/dL at initiation 3) renal insufficiency
57
Monitoring with aldosterone antagonists
1) titrate every 4-8 wks twd target dose 2) monitor BMP 3-7 days after start of therapy, the once monthly for 3 mo., then periodically as needed (significant rights of hyperkalemia)
58
When should you use BB clinically in regards to HF?
1) in pt. w/ MI and reduced EF, use BB to prevent HF 2) in all pt. with reduced EF (use of 1 of the 3 BB proven to reduce mortality is recommended for all stable pt)
59
What are the 3 BB proven to reduce mortality in pt. at risk for HF?
bisoprolol, carvedilol, and metoprolol succinate
60
What is a good alternative if pt. is hypotensive on carvedilol or cannot tolerate lower BP?
metoprolol succinate **also good for pt. w/ Afib, COPD, asthma
61
adrenergic activation is lethal in __________
chronic HF (why we use beta-blockers) *pt. with highest NE levels have worst prognosis
62
BB C/I
1) cardiogenic shock 2) symptomatic bradycardia 3) 2nd/3rd degree heart block w/out pacemaker 4) severe reactive airway dz * use w/ considerable caution in pt. w/ < 55 bpm or SBP < 80 mmHg * NOT recommended in pt. with asthma with active bronchospasm
63
BB s/e
1) fatigue, weakness, lassitude 2) fluid retention 3) bradycardia 4) volume overload vs. COPD
64
Introducing BB to pt.
titrate every 2-4 wks toward target dose may need to adjust diuretic dose
65
Monitoring with BB
BP, HR, HF sx, weights
66
Hydralazine class
arteriolar dilator antioxidant (inhibits destruction of NO)
67
Isosorbide dinitrate (ISDN) class
venous dilator large and small a. dilator NO doner
68
BiDil
NO enhancer **This is a combination drug that is a fixed dose of isosorbide dinitrate + hydralazine
69
Hydralazine s/e
hypotension, HA, tachycardia (less in HF), lupus like syndrome (+ANA)
70
Nitrates s/e
hypotension, HA, flushing, tolerance
71
Hydralazine, ISDN, BiDil are NOT recommended unless
pt. are unable to tolerate ACEI
72
When is Digoxin recommended?
HF with concurrent Afib **controversy to use in normal rhythm (SE risk vs. benefit)
73
Digoxin MOA
unclear - prob. NOT d/t positive inotropic effect - likely benefits from neurohormonal inhibition
74
Target peak concentration (Cp) of Digoxin
0.5-0.8 ng/mL
75
T/F in clinical trials Digoxin use showed an increase rate of survival
FALSE No survival benefit was seen at 4 yrs (although it did reduce symptomatic progression)
76
Clinical benefits seen from digoxin use
1) improved sx 2) improved exercise tolerance 3) improved QOL 4) decr. hospitalizations ***there is NO survival benefit
77
Digoxin s/e
CNS = HA, dizziness, halos, changes in yellow/green color perception GI = anorexia, N/V, diarrhea, constipation Cardiac = bradycardia (AV block), HR < 50, incr. PR interval
78
Risk factors for digoxin toxicity
renal insufficiency, hypokalemia/hyperkalemia, drug interactions
79
Digoxin interactions
See incr. serum concentration w/ amiodarone, erythromycin, itraconazole, omeprazole See decr. serum concentrations w/ antacids, colestipol, laxatives
80
Which HF drugs should be considered in AA population?
hydralazine/ISDN
81
If EF < 35% despite optimized std therapy, consider
ICD
82
Tx protocol of HFpEF
1) tx physological factors (BP, HR, blood volume, ischemia) 2) tx dz known to cz HFpEF (HTN, CAD) 3) use of anticoagulation and anti-arrhythmic recommendations apply to all pt. w/ HF **lack of randomized controlled trials
83
Hawthorn (Crataegus oxycantha) uses
CHF, angina, arrhythmias, hyperlipidemia, Buerger's dz
84
Hawthorn (Crataegus oxycantha) adverse effects
hypotension, palpitations, progression of HF
85
Crataegus oxycantha interactions
1) w/ BB, CCB, PDE-5 inhibitors, nitrates - decreases BP, dizziness, and/or light headedness 2) w/ antiplatelet/anticoagulants - incr. bleeding risk
86
Hypericum uses
depression, anxiety, sleep d/o, HIV
87
Hypericum s/e
arrhythmia and HTN
88
Hypericum interactions
w/ Digoxin, Statins, Verapamil, Warfarin, ARB, BB - decr. levels of drug
89
CAMs that may be mechanistically harmful in HF
aconite, ginseng, gossypol, gynura, licorice, lily of the valley, tetrandrine, yohimbine

Pharmacology (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions